The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature
Open accessAbstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects motor and cognition functions. The etiology of Parkinson's disease remains largely unknown, but genetic and environmental factors are believed to play a role. The neurotransmitter dopamine is implicated in regulating movement, motivation, memory, and other physiological processes. In individuals with Parkinson's disease, the loss of dopaminergic neurons leads to a reduction in dopamine levels, which causes motor impairment and may also contribute to the cognitive deficits observed in some patients. Therefore, it is important to understand the pathophysiology that leads to the loss of dopaminergic neurons, along with reliable biomarkers that may help distinguish PD from other conditions, monitor its progression, or indicate a positive response to a therapeutic intervention. Important advances in the treatment, etiology, and pathogenesis of Parkinson's disease have been made in the past 50 years. Therefore, this review tries to explain the different possible mechanisms behind the depletion of dopamine in PD patients such as alpha-synuclein abnormalities, mitochondrial dysfunction, and 3,4-dihydroxyphenylacetaldehyde (DOPAL) toxicity, along with the current therapies we have and the ones that are in development. The clinical aspect of Parkinson's disease such as the manifestation of both motor and non-motor symptoms, and the differential diagnosis with similar neurodegenerative disease are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“There is strong evidence that Lewy pathology is associated with cognitive impairment in Parkinson’s disease [19].”
BackgroundKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,359
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., Zaccai, J., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,689
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
DOPAMINE (3-HYDROXYTYRAMINE) AND BRAIN FUNCTION
HORNYKIEWICZ, O. (1966) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07154-6 · Cited by 1,442
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081564 · Cited by 1,408
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
Variable expression of Parkinson's disease: A base‐line analysis of the DAT ATOP cohort
Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., et al. (1990) · Neurology · doi:10.1212/wnl.40.10.1529 · Cited by 1,285
Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., Chaudhry, F. A., Nicoll, R. A., & Edwards, R. H. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.023 · Cited by 1,056
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Bronstein, J. M., Tagliati, M., Alterman, R. L., Lozano, A. M., Volkmann, J., Stefani, A., Horak, F. B., Okun, M. S., Foote, K. D., Krack, P., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.260 · Cited by 971
Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002350 · Cited by 870
Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865
Prion-like transmission of protein aggregates in neurodegenerative diseases
Brundin, P., Melki, R., & Kopito, R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2873 · Cited by 778
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Genetics of Parkinson disease: paradigm shifts and future prospects
Farrer, M. J. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1831 · Cited by 707
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Dopamine visualized in the basal ganglia of living man
Garnett, E. S., Firnau, G., & Nahmias, C. (1983) · Nature · doi:10.1038/305137a0 · Cited by 644
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
ΔΨ m ‐Dependent and ‐independent production of reactive oxygen species by rat brain mitochondria
Votyakova, T. V., & Reynolds, I. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00548.x · Cited by 601
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448 · cited 1×
“SPD, as have genetic factors such as polymorphisms in genes such as GBA, SNCA, and LRRK2, among others [5].”
BackgroundDeterminants of dopaminergic neuron loss in Parkinson's disease
Surmeier, D. J. (2018) · The FEBS Journal · doi:10.1111/febs.14607 · Cited by 444
Parkinson’s disease: The non-motor issues
Chaudhuri, K. R., Odin, P., Antonini, A., & Martinez-Martin, P. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.02.018 · Cited by 388
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365 · cited 1×
“Although no data from randomized clinical trials (RCT) currently exists on the use of cannabinoids to treat non-motor symptoms in PD, RCTs that have evaluated the impact of cannabinoids on quality of life in Parkinson’s disease patients have reported either an improvement or no benefit [66].”
BackgroundFetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
Barker, R. A., Barrett, J., Mason, S. L., & Björklund, A. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70295-8 · Cited by 365
Xilouri, M., Vogiatzi, T., Vekrellis, K., Park, D., & Stefanis, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005515 · Cited by 354
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 328
Role of α-Synuclein in Presynaptic Dopamine Recruitment
Yavich, L., Tanila, H., Vepsäläinen, S., & Jäkälä, P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2559-04.2004 · Cited by 316
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25095 · Cited by 315
Cell-based therapies for Parkinson disease—past insights and future potential
Barker, R. A., Drouin-Ouellet, J., & Parmar, M. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.123 · Cited by 306
α-Synuclein and dopamine at the crossroads of Parkinson's disease
Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade-Martins, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.004 · Cited by 285
Khaliq, Z. M., & Bean, B. P. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0143-10.2010 · Cited by 261
Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M., & Soto, C. (2023) · Nature Protocols · doi:10.1038/s41596-022-00787-3 · Cited by 240
Imaging Approaches to Parkinson Disease
Brooks, D. J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.059998 · Cited by 234
Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., Santic, R., Meindl, S., Vigl, B., Smrzka, O., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1256-4 · Cited by 229
Liang, C.-L., Wang, T. T., Luby-Phelps, K., & German, D. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.015 · Cited by 185
Neuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25187 · Cited by 184
Imaging in Parkinson’s disease
Pagano, G., Niccolini, F., & Politis, M. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-4-371 · Cited by 178
Premotor Parkinson’s disease: Concepts and definitions
Siderowf, A., & Lang, A. E. (2012) · Movement Disorders · doi:10.1002/mds.24954 · Cited by 174
Schapira, A. H. V. (2011) · CNS Drugs · doi:10.2165/11596310-000000000-00000 · Cited by 162
Alcalay, R. N., Caccappolo, E., Mejia‐Santana, H., Tang, M. X., Rosado, L., Ross, B. M., Verbitsky, M., Kisselev, S., Louis, E. D., Comella, C. L., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.194 · Cited by 147
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
Barker, R. A., Björklund, A., Gash, D. M., Whone, A. L., Laar, A. D. V., Kordower, J. H., Bankiewicz, K. S., Kieburtz, K. D., Saarma, M., Booms, S., et al. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202004 · Cited by 145
Stover, N. P., Bakay, R. A. E., Subramanian, T., Raiser, C. D., Cornfeldt, M. L., Schweikert, A. W., Allen, R. C., & Watts, R. L. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.1833 · Cited by 140
The Role of α‐Synuclein in Both Neuroprotection and Neurodegeneration
Sidhu, A., Wersinger, C., Moussa, C., & Vernier, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.016 · Cited by 115
Novel formulations and modes of delivery of levodopa
Poewe, W. H., & Antonini, A. (2014) · Movement Disorders · doi:10.1002/mds.26078 · Cited by 108
An endogenous dopaminergic neurotoxin: Implication for Parkinson's disease
Mattammal, M. B., Haring, J. H., Chung, H. D., Raghu, G., & Strong, R. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90016-0 · Cited by 108
Heo, J. Y., Park, J. H., Kim, S. J., Seo, K. S., Han, J., Lee, S. H., Kim, J., Park, J., Park, S. K., Lim, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032629 · Cited by 105
Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience
Balash, Y., Schleider, L. B., Korczyn, A. D., Shabtai, H., Knaani, J., Rosenberg, A., Baruch, Y., Djaldetti, R., Giladi, N., & Gurevich, T. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000246 · Cited by 82
Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
Stocchi, F., & Olanow, C. W. (2013) · Movement Disorders · doi:10.1002/mds.25337 · Cited by 70
Barker, R. A., Studer, L., Cattaneo, E. F., & Takahashi, J. B. (2015) · npj Parkinson s Disease · doi:10.1038/npjparkd.2015.17 · Cited by 66
Rehman, H. U. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.908.379 · Cited by 57
Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First
Monje, M. H. G., Sánchez‐Ferro, Á., Pineda‐Pardo, J. A., Vela, L., Alonso‐Frech, F., & Obeso, J. A. (2021) · Movement Disorders · doi:10.1002/mds.28462 · Cited by 56
Goldstein, D. S., Jinsmaa, Y., Sullivan, P., Holmes, C. S., Kopin, I. J., & Sharabi, Y. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230201 · Cited by 44
Sudden unexpected death in Parkinson's disease: Insights from clinical practice
Scorza, F. A., Guimarães‐Marques, M., Nejm, M. B., de Almeida, A.-C. G., Scorza, C. A., FIORINI, A. C., & Finsterer, J. (2022) · Clinics · doi:10.1016/j.clinsp.2021.100001 · Cited by 23
Cited by
Vignando, M., Ffytche, D., Mazibuko, N., Palma, G., Bhat, A., Montagnese, M., Dave, S., Tai, Y. F., Batzu, L., Leta, V., et al. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00669-7
“The aim of this analysis was to test, in an exploratory and hypothesis-generating way, whether EEG activity during the vMMN task relates to the distribution of neurotransmitter receptors implicated in PD with VH, namely the serotonergic 42,43 , dopaminergic 71 and cholinergic 57 systems.”
Metadata
- Authors
- Ramesh, S., & Arachchige, A. S. P. M.
- Venue
- AIMS Neuroscience
- Published
- 2023
- Volume
- 10
- Issue
- 3
- Pages
- 200-231
- ISSN
- 2373-7972 (ISSN-L)
- OpenAlex
- W4385844167
- Cited by
- 289
- References
- 69
- FWCI
- 42.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.